返回 
加入收藏
达格列净治疗稳定性冠心病合并心力衰竭的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 达格列净治疗稳定性冠心病合并心力衰竭的临床观察 |
| TITLE： | Clinical observation of dapagliflozin for stable coronary heart disease combined with heart failure |
| 摘要： | 目的 探讨达格列净治疗稳定性冠心病合并心力衰竭（HF）患者的临床疗效。方法采用前瞻性研究法，将2023年1月1日至2024年1月1日我院收治的稳定性冠心病合并HF患者158例按照随机数字表法分为达格列净组（n＝76）和常规治疗组（n＝82）。所有患者均接受利尿剂、阿司匹林、氯沙坦、美托洛尔、他汀类药物等常规治疗；达格列净组患者在常规治疗基础上联用达格列净片，每次10mg，每天1次；疗程均为6个月。比较两组患者治疗前后左室射血分数（LVEF）、左室收缩末期内径（LVESD）、左室舒张末期内径（LVEDD）、空腹血糖、氨基末端脑利钠肽前体（NT-proBNP）、心绞痛发作次数、心绞痛发作持续时间、脂蛋白相关磷脂酶A2等指标的变化，并评估两组患者治疗期间肾功能不全、肝功能不全、泌尿系统感染、新发透析、低血压、低血糖等不良反应的发生情况。结果治疗过程中共有16例患者脱落，最终达格列净组70例、常规治疗组72例患者完成研究。治疗前，两组患者上述各项指标比较，差异均无统计学意义（P＞0.05）。与治疗前相比，治疗后两组患者的LVESD、LVEDD均显著缩短，LVEF均显著升高，NT-proBNP、脂蛋白相关磷脂酶A2水平均显著降低，心绞痛发作次数、心绞痛发作持续时间均显著减少（P＜0.05），且达格列净组患者较常规治疗组改善得更为明显（P＜0.05）。两组患者的空腹血糖水平以及上述各项不良反应发生率比较，差异均无统计学意义（P＞0.05）。结论在常规治疗上加用达格列净能够缩短稳定性冠心病合并HF患者的LVESD、LVEDD，提高LVEF水平，降低NT-proBNP、脂蛋白相关磷脂酶A2水平，减少心绞痛发作次数和心绞痛持续时间，从而改善其心功能，且安全性较好。 |
| ABSTRACT： | OBJECTIVE To explore the clinical efficacy of dapagliflozin for stable coronary heart disease combined with heart failure （HF）. METHODS A prospective study method was employed. A total of 158 patients with stable coronary heart disease and HF admitted to our hospital from January 1， 2023， to January 1， 2024， were enrolled. Using a random number table method， they were divided into dapagliflozin group （n＝76） and conventional treatment group （n＝82）. All patients received conventional treatment， including diuretic， aspirin， losartan， metoprolol and statins. Patients in the dapagliflozin group were additionally administered Dapagliflozin tablets at a dose of 10 mg once daily on top of the conventional treatment. The treatment duration was six months. The changes in left ventricular ejection fraction （LVEF）， left ventricular end-systolic diameter （LVESD）， left ventricular end-diastolic diameter （LVEDD）， fasting blood glucose， N-terminal pro-brain natriuretic peptide （NT-proBNP）， the number of angina attacks， the duration of angina attacks， and lipoprotein-associated phospholipase A2 before and after treatment were compared between the two groups. The occurrence of adverse reactions such as renal dysfunction， liver dysfunction， urinary system infections， new-onset dialysis， hypotension and hypoglycemia was evaluated in the two groups during treatment. RESULTS During the study， 16 patients were lost to follow-up. Ultimately， 70 patients in the dapagliflozin group and 72 patients in the conventional treatment group completed the study. Before treatment， there were no statistically significant differences in the aforementioned indicators between the two groups （P＞0.05）. Compared with before treatment， after treatment， both groups showed significant shortening in LVESD and LVEDD， significant increases in LVEF， significant reductions in NT-proBNP and lipoprotein-associated phospholipase A2 levels， and significant reductions in the number of angina attacks and the duration of angina attacks （P＜0.05）； the improvements in the dapagliflozin group were more significant than those in the conventional treatment group （P＜0.05）. There was no statistically significant difference between the two groups in fasting blood glucose levels and the incidence of the aforementioned adverse reactions （P＞0.05）. CONCLUSIONS Adding dapagliflozin to conventional treatment can shorten LVESD and LVEDD， increase LVEF levels， reduce NT-proBNP and lipoprotein-associated phospholipase A2 levels， and decrease the number and duration of angina attacks in patients with stable coronary heart disease combined with HF， thereby improving their cardiac function， and demonstrates good safety. |
| 期刊： | 2025年第36卷第11期 |
| 作者： | 董耀辉；胡钢；王晓慧 |
| AUTHORS： | DONG Yaohui，HU Gang，WANG Xiaohui |
| 关键字： | 达格列净；稳定性冠心病；心力衰竭；心功能；临床疗效 |
| KEYWORDS： | dapagliflozin； stable coronary heart disease； |
| 阅读数： | 9 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
